SCHEMBL1962583

SCHEMBL1962583

Cc1ccc(S(=O)(=O)OC(=CC2CCCC2)c2cc3cc(C)cnc3n2S(=O)(=O)c2ccccc2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.36
NOD2 Q9HC29 2/20 0.36
NOD1 Q9Y239 2/20 0.36
PSEN1 P49768 1/20 0.34
PSEN2 P49810 1/20 0.34
APH1B Q8WW43 1/20 0.34
NCSTN Q92542 1/20 0.34
APH1A Q96BI3 1/20 0.34
PSENEN Q9NZ42 1/20 0.34
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
PDE5A O76074 1/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
ALDH3A1 P30838 1/20 0.32
GAA P10253 2/20 0.32
ALDH1A1 P00352 4/20 0.32
HPGD P15428 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1962581 1.00 ALOX5 (0.36) ALOX5NOD2NOD1PSEN1PSEN2
SCHEMBL1960760 0.93 ALOX5 (0.35) ALOX5NOD2NOD1PSEN1PSEN2
SCHEMBL1960759 0.93 ALOX5 (0.35) ALOX5NOD2NOD1PSEN1PSEN2
SCHEMBL1961132 0.92 LMNA (0.36) ALOX5NOD2NOD1PSEN1PSEN2
SCHEMBL1960504 0.91 LMNA (0.36) ALOX5NOD2NOD1PSEN1PSEN2
SCHEMBL1960503 0.91 LMNA (0.36) ALOX5NOD2NOD1PSEN1PSEN2
SCHEMBL1963699 0.90 MEN1 (0.35) ALOX5NOD2NOD1KMT2AMEN1
SCHEMBL1963698 0.90 MEN1 (0.35) ALOX5NOD2NOD1KMT2AMEN1
SCHEMBL1963603 0.90 L3MBTL1 (0.39) ALOX5NOD2NOD1KMT2AMEN1
SCHEMBL1961211 0.90 L3MBTL1 (0.39) ALOX5NOD2NOD1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2513103-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2012-10-24 EP disclosed
US-8222416-B2 Azaindole glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2012-07-17 US disclosed
WO-2011073117-A1 AZAINDOLE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 WO disclosed
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2011-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144105-A1 AZAINDOLE GLUCOKINASE ACTIVATORS GCK, GCKR, GALK1 ALOX5 1778/4885NOD2 4541/4885NOD1 4386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.